Abstract
Glioblastoma multiforme (GBM) is the most common primary tumour of the central nervous system. The outcome after standard therapy, consisting of resection, radiation and chemotherapy, is poor: median survival is 40 to 60 weeks, with the tumour often recurring only a few millimetres away from the original location after gross total resection. The epidermal growth factor receptor (EGFR) is amplified and overexpressed in 40% to 50% of GBM, almost half of which co-expresses the mutated, constitutively activated EGFR variant III (EGFRvIII). As EGFR activation leads to cell proliferation, angiogenesis and reduced apoptosis, its increased activity may contribute to the aggressiveness of GBM. Therefore, to control these carcinogenic functions through EGFR inhibition is a logical therapeutic approach. Various trials of EGFR antagonists are ongoing, investigating tyrosine kinase inhibitors (TKIs), monoclonal antibodies (MAbs), RNA-based agents and vaccination against EGFRvIII. While TKIs, e.g. erlotinib and gefitinib, are currently the most advanced in clinical development, numerous trials indicate that a multiple target approach might be necessary to achieve therapeutically relevant effects.
Keywords: Combined therapy, epidermal growth factor receptor, EGFRvIII, erlotinib, glioblastoma multiforme, multitargeting, tyrosine kinase inhibitors, glioblastoma treatment, RNA-based agents, primary tumor
Current Signal Transduction Therapy
Title: Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Volume: 7 Issue: 1
Author(s): N. Merkur, M.-A. Westhoff, G. Karpel-Massler and M.-E. Halatsch
Affiliation:
Keywords: Combined therapy, epidermal growth factor receptor, EGFRvIII, erlotinib, glioblastoma multiforme, multitargeting, tyrosine kinase inhibitors, glioblastoma treatment, RNA-based agents, primary tumor
Abstract: Glioblastoma multiforme (GBM) is the most common primary tumour of the central nervous system. The outcome after standard therapy, consisting of resection, radiation and chemotherapy, is poor: median survival is 40 to 60 weeks, with the tumour often recurring only a few millimetres away from the original location after gross total resection. The epidermal growth factor receptor (EGFR) is amplified and overexpressed in 40% to 50% of GBM, almost half of which co-expresses the mutated, constitutively activated EGFR variant III (EGFRvIII). As EGFR activation leads to cell proliferation, angiogenesis and reduced apoptosis, its increased activity may contribute to the aggressiveness of GBM. Therefore, to control these carcinogenic functions through EGFR inhibition is a logical therapeutic approach. Various trials of EGFR antagonists are ongoing, investigating tyrosine kinase inhibitors (TKIs), monoclonal antibodies (MAbs), RNA-based agents and vaccination against EGFRvIII. While TKIs, e.g. erlotinib and gefitinib, are currently the most advanced in clinical development, numerous trials indicate that a multiple target approach might be necessary to achieve therapeutically relevant effects.
Export Options
About this article
Cite this article as:
Merkur N., Westhoff M.-A., Karpel-Massler G. and Halatsch M.-E., Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment, Current Signal Transduction Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157436212799278034
DOI https://dx.doi.org/10.2174/157436212799278034 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters Computational Methods for DNA-binding Protein and Binding Residue Prediction
Protein & Peptide Letters Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Cadmium-containing Quantum Dots: Current Perspectives on Their Application as Nanomedicine and Toxicity Concerns
Mini-Reviews in Medicinal Chemistry N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Chaperoning the Cancer: The Proteostatic Functions of the Heat Shock Proteins in Cancer
Recent Patents on Anti-Cancer Drug Discovery Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy Nongenomic Actions of Thyroid Hormones: Every why has a Wherefore
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives
Current Medicinal Chemistry Anti-MDR Effects of Quercetin and its Nanoemulsion in Multidrug-Resistant Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry 5-HT3 Receptors
Current Pharmaceutical Design Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
Current Neuropharmacology Rational Drug Design for Identifying Novel Multi-target Inhibitors for Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Trichostatin A - like Hydroxamate Histone Deacetylase Inhibitors as Therapeutic Agents: Toxicological Point of View
Current Medicinal Chemistry Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets